ReviewDrug discovery today2014
DREADDs: novel tools for drug discovery and development.
Review in Drug discovery today, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Neuromodulation in Small Animal fMRI.Journal of magnetic resonance imaging : JMRI · 2025Review
- Neuroprotective Role of Cyclic AMP Signaling in Dopaminergic Degeneration Induced by a Parkinson's Disease Toxin, Rotenone.NeuroSci · 2025Article
- Dermal TRPV1 innervations engage a macrophage- and fibroblast-containing pathway to activate hair growth in mice.Developmental cell · 2024Article
- Astrocytic activation increases blood flow in the adult olfactory bulb.Molecular brain · 2024Article
- G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery.Signal transduction and targeted therapy · 2024Review
- V2a neurons restore diaphragm function in mice following spinal cord injury.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Activation of cyclic AMP signaling pathway in dopaminergic neurons rescues locomotion defects in a Drosophila larval model of Parkinson's disease.Brain research · 2024Article
- Multiple Subthreshold GPCR Signals Combined by the G-Proteins GαThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- Chemogenetic inhibition of corticotropin-releasing factor neurons in the central amygdala alters binge-like ethanol consumption in male mice.Behavioral neuroscience · 2022Article
- eIF2-dependent translation initiation: Memory consolidation and disruption in Alzheimer's disease.Seminars in cell & developmental biology · 2022Review
- Chemogenetic manipulation of astrocytic signaling in the basolateral amygdala reduces binge-like alcohol consumption in male mice.Journal of neuroscience research · 2021Article
- Control of impulsivity by GCommunications biology · 2021Article
- Translational PET applications for brain circuit mapping with transgenic neuromodulation tools.Pharmacology, biochemistry, and behavior · 2021Review
- The frontier of live tissue imaging across space and time.Cell stem cell · 2021Review
- CRISPR, Prime Editing, Optogenetics, and DREADDs: New Therapeutic Approaches Provided by Emerging Technologies in the Treatment of Spinal Cord Injury.Molecular neurobiology · 2020Review
- Development of a high-throughput arrayed neural circuitry platform using human induced neurons for drug screening applications.Lab on a chip · 2020Article
- The PVN enhances cardiorespiratory responses to acute hypoxia via input to the nTS.American journal of physiology. Regulatory, integrative and comparative physiology · 2019Article
- β-blockers augment L-type CaeLife · 2019Article
- A Comparative Study of the Pharmacokinetics of ClozapineThe Journal of pharmacology and experimental therapeutics · 2019Article
- GTL-1, a Calcium Activated TRPM Channel, Enhances Nociception.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Since the invention of the first designer receptors exclusively activated by designer drugs (DREADDs), these engineered G protein-coupled receptors (GPCRs) have been widely applied in investigations of biological processes and behaviors. DREADD technology has emerged as a powerful tool with great potential for drug discovery and development. DREADDs can facilitate the identification of druggable targets and enable researchers to explore the activities of novel drugs against both known and orphan GPCRs. Here, we discuss how DREADDs can be used as novel tools for drug discovery and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.